Plant Name: Asteriscus graveolens
Taxonomic Information:
Plant ID: NPO24501
Plant Latin Name: Asteriscus graveolens
Taxonomy Genus: Asteriscus
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
73976
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD3; | |
| ALPL; | |
| AXL; SRC; IGF1R; PTK2; MAPK1; ALK; KDR; | |
| CA2; CA14; | |
| NFKB1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.501E-08 | 4.669E-05 | IGF1R, KDR, PTK2, SRC |
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 4.671E-08 | 7.824E-05 | ALK, AXL, IGF1R, KDR |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 8.586E-08 | 1.169E-04 | AXL, KDR, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 4.662E-07 | 4.230E-04 | AXL, KDR, MAPK1, NFKB1, SRC |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 4.254E-06 | 2.370E-03 | IGF1R, KDR, MAPK1, PTK2, SRC |
| BP | GO:0022610; biological adhesion | GO:0051893; regulation of focal adhesion assembly | 4.463E-06 | 2.370E-03 | KDR, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 5.281E-06 | 2.613E-03 | AXL, CA2, KDR, MAPK1, SRC |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.043E-06 | 2.633E-03 | CA2, DRD3, KDR, SRC |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 8.470E-06 | 3.236E-03 | ALK, AXL, IGF1R, KDR, MAPK1, PTK2, SRC |
| BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 1.425E-05 | 4.371E-03 | AXL, CA2, MAPK1, NFKB1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0060159; regulation of dopamine receptor signaling pathway | 1.588E-05 | 4.736E-03 | ALK, DRD3 |
| BP | GO:0009987; cellular process | GO:0038127; ERBB signaling pathway | 1.637E-05 | 4.816E-03 | MAPK1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0045595; regulation of cell differentiation | 2.193E-05 | 5.824E-03 | AXL, CA2, DRD3, KDR, MAPK1, NFKB1, PTK2 |
| BP | GO:0050896; response to stimulus | GO:0038166; angiotensin-activated signaling pathway | 2.327E-05 | 6.032E-03 | CA2, SRC |
| BP | GO:0009987; cellular process | GO:0014066; regulation of phosphatidylinositol 3-kinase signaling | 2.614E-05 | 6.467E-03 | KDR, MAPK1, PTK2 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 3.605E-05 | 8.198E-03 | AXL, MAPK1, SRC |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 3.614E-05 | 8.198E-03 | AXL, CA2, KDR, MAPK1, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.698E-05 | 8.302E-03 | CA14, CA2 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.808E-05 | 8.345E-03 | AXL, MAPK1, SRC |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 4.225E-05 | 8.762E-03 | PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 4.728E-05 | 9.532E-03 | ALPL, MAPK1, NFKB1, SRC |
| BP | GO:0051179; localization | GO:2000641; regulation of early endosome to late endosome transport | 4.787E-05 | 9.534E-03 | MAPK1, SRC |
| BP | GO:0050896; response to stimulus | GO:0071222; cellular response to lipopolysaccharide | 4.816E-05 | 9.534E-03 | AXL, NFKB1, SRC |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 4.938E-05 | 9.687E-03 | AXL, KDR, NFKB1 |
| MF | Unclassified; | GO:0005057; signal transducer activity, downstream of receptor | 5.188E-05 | 9.997E-03 | ALK, KDR, MAPK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 3.806E-08 | 3.168E-06 | SRC, KDR, MAPK1, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 7.666E-08 | 3.168E-06 | SRC, KDR, MAPK1, PTK2, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 7.479E-08 | 3.168E-06 | SRC, KDR, MAPK1, PTK2, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.004E-06 | 3.114E-05 | KDR, MAPK1, PTK2, NFKB1, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 3.455E-06 | 8.568E-05 | SRC, MAPK1, NFKB1, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 5.578E-06 | 1.153E-04 | SRC, KDR, MAPK1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.449E-06 | 1.155E-04 | KDR, MAPK1, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 9.615E-06 | 1.295E-04 | SRC, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 7.059E-06 | 1.155E-04 | SRC, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.820E-05 | 1.881E-04 | MAPK1, NFKB1, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.044E-05 | 1.295E-04 | SRC, MAPK1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.700E-05 | 1.881E-04 | SRC, MAPK1, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 6.672E-05 | 5.516E-04 | MAPK1, NFKB1, PTK2, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.822E-05 | 2.691E-04 | MAPK1, NFKB1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 7.989E-05 | 6.191E-04 | SRC, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.181E-04 | 1.423E-03 | SRC, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 1.437E-04 | 1.024E-03 | SRC, MAPK1, NFKB1 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 2.475E-04 | 1.534E-03 | SRC, MAPK1, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.486E-04 | 1.024E-03 | NFKB1, PTK2, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 4.331E-04 | 2.441E-03 | SRC, KDR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 4.992E-04 | 2.565E-03 | ALK, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 6.722E-04 | 3.069E-03 | MAPK1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 5.171E-04 | 2.565E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 5.729E-04 | 2.732E-03 | MAPK1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 6.929E-04 | 3.069E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.671E-04 | 1.577E-03 | SRC, MAPK1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 8.470E-04 | 3.183E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.014E-04 | 3.183E-03 | MAPK1, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 5.171E-04 | 2.565E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.354E-04 | 3.145E-03 | SRC, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 8.470E-04 | 3.183E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 8.470E-04 | 3.183E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.312E-03 | 4.171E-03 | SRC, MAPK1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.612E-03 | 4.544E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.519E-03 | 4.544E-03 | MAPK1, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.399E-03 | 4.337E-03 | NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.173E-03 | 3.931E-03 | NFKB1, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 9.662E-04 | 3.423E-03 | SRC, PTK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.550E-03 | 4.544E-03 | SRC, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 8.938E-04 | 3.260E-03 | MAPK1, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.228E-03 | 4.006E-03 | SRC, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 1.173E-03 | 3.931E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 1.581E-03 | 4.544E-03 | NFKB1, PTK2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.708E-03 | 4.605E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.774E-03 | 4.680E-03 | MAPK1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.908E-03 | 4.930E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.708E-03 | 4.605E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.192E-03 | 5.402E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.265E-03 | 5.402E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.192E-03 | 5.402E-03 | SRC, MAPK1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.340E-03 | 5.461E-03 | SRC, MAPK1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 2.378E-03 | 5.461E-03 | MAPK1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.265E-03 | 5.402E-03 | MAPK1, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.067E-03 | 6.445E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 2.732E-03 | 5.929E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.773E-03 | 5.929E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 2.533E-03 | 5.710E-03 | MAPK1, PTK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 3.886E-03 | 7.899E-03 | SRC, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.773E-03 | 5.929E-03 | MAPK1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 4.743E-03 | 9.486E-03 | MAPK1, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 3.153E-03 | 6.517E-03 | MAPK1, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.466E-05 | 3.955E-04 | CA2, CA14 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PTK2; IGF1R; KDR; MAPK1; SRC; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | IGF1R; KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTK2; IGF1R; KDR; NFKB1; MAPK1; SRC; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
